Zimmer Biomet came into this print with the stock already rebuilding confidence, up strongly over the past quarter, and it added another 2.5% today. That price move sits against a quarter where adjusted earnings per share were flat at $2.07 even as management lifted full year guidance. The real story is not a blowout profit number. It is a company leaning hard into growth investments that are compressing margins now while top line orthopedics demand and cash generation continue to support a lower than peer P/E multiple.

Is Zimmer Biomet Holdings trading at a genuine discount, or is the lower P/E simply compensation for slower growth and higher debt risk? See how those trade offs show up in our valuation analysis for Zimmer Biomet Holdings

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$2,177.0m vs. US$2,077.3m (up about 4.8%)
• Net Income, Q2 2026 vs. Q2 2025: US$198.3m vs. US$152.8m (up about 29.8%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$1.03 vs. US$0.77 (up about 33.8%)
• Adjusted Operating Margin, Q2 2026 vs. Q2 2025: 25.7% vs. 27.8% (margin compressed by about 210 basis points, reflecting higher growth investment and increased manufacturing costs at Zimmer Biomet)

Prefer clear charts instead of another dense wall of earnings tables and margin figures? See Zimmer Biomet Holdings' full financial picture with a visual breakdown of its valuation in the company report for Zimmer Biomet Holdings.

Zimmer Biomet earnings support measured growth story

Zimmer Biomet is starting to back up the growth narrative with actual numbers. Revenue rose 4.8% year on year and Tech & Data plus related products climbed 21.5%, which fits the idea of a robotics and digital platform gaining traction on top of a large implant base. Hips and S.E.T. contributed, while management felt confident enough to raise full year revenue and EPS guidance. Cash generation also moved higher, with free cash flow up 24%, which supports the view that the business model is funding its own reinvestment.

Margins and mix keep bearish worries in play

Bearish arguments around profitability and execution are not swept away. Adjusted operating margin compressed by about 210 basis points as Zimmer Biomet leaned into growth investments and handled higher manufacturing costs. Knees were essentially flat, which shows not every core franchise is firing. Pricing remained a headwind at roughly 80 basis points in the quarter. The raised outlook and strong cash flow suggest risks appear manageable for now, but the margin trend and mixed volume picture keep the pressure on management to prove that current spending will translate into more durable growth.

Review Zimmer Biomet Holdings margin pressure and debt exposure, then scan for potential hidden structural warning signs inside our risk analysis for Zimmer Biomet Holdings which shows 2 important warning signs.

Take Control Of Your Next Move

If Zimmer Biomet Holdings looks interesting after this mix of higher revenue, margin pressure and raised guidance, register for free with Simply Wall St and add it to your Watchlist to track share price against fair value and watch how the thesis evolves. Once you decide to build a position, use the Portfolio Command Center to cut through day to day noise and focus on the most important developments that could affect your holdings. For a broader perspective on Zimmer Biomet and similar stocks, turn to the Community and see how other investors are thinking about the same risks and opportunities. That way you can spot potential catalysts or early warning signs sooner and stay ahead of the market.

Seeking Alternatives Beyond Zimmer Biomet

Fresh ideas can gain attention quickly when momentum builds and solid businesses start breaking out under the radar. Review these curated stock sets before the crowd moves and consider your options early.

• Review resilient compounders with muted volatility in the hand picked 79 resilient stocks with low risk scores before they appear on everyone else’s radar and potential entry points become less attractive.
• Look for steady income from businesses with substantial cash reserves in the curated 8 dividend fortresses while yields remain appealing and before momentum investors crowd the space.
• Explore companies funding real growth instead of persistent cash burn through the focused 67 profitable AI stocks that aren't just burning cash while some of the more compelling entries are still less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.